AstraZeneca Shares Decline After HSBC Downgrades Rating Due to Wainua Trial Setback
HSBC downgraded its rating for AstraZeneca (NASDAQ:AZN) from Buy to Hold following disappointing Phase 3 results of the Wainua trial, causing a drop in both London and U.S. listed shares by approximately 1%. The downgrade reflects concerns over future clinical milestones impacting revenue projections.
Topics: AstraZeneca HSBC downgrade stock price movement Wainua Phase 3 results